329 related articles for article (PubMed ID: 24748775)
1. A review of denosumab for the treatment of osteoporosis.
Miyazaki T; Tokimura F; Tanaka S
Patient Prefer Adherence; 2014; 8():463-71. PubMed ID: 24748775
[TBL] [Abstract][Full Text] [Related]
2. Skeletal and extraskeletal actions of denosumab.
Sinningen K; Tsourdi E; Rauner M; Rachner TD; Hamann C; Hofbauer LC
Endocrine; 2012 Aug; 42(1):52-62. PubMed ID: 22581255
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
Bai YD; Yang FS; Xuan K; Bai YX; Wu BL
Med Hypotheses; 2008 Aug; 71(2):256-8. PubMed ID: 18445511
[TBL] [Abstract][Full Text] [Related]
4. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
Varenna M; Gatti D
Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563
[TBL] [Abstract][Full Text] [Related]
5. Anti-RANKL antibody was approved for the treatment of osteoporosis in Japan.
Yasuda H
Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(4):209-16. PubMed ID: 23994799
[TBL] [Abstract][Full Text] [Related]
6. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
7. Can denosumab be a substitute, competitor, or complement to bisphosphonates?
Kim SY; Ok HG; Birkenmaier C; Kim KH
Korean J Pain; 2017 Apr; 30(2):86-92. PubMed ID: 28416991
[TBL] [Abstract][Full Text] [Related]
8. [The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis - possible applications of anti-RANKL antibody to the treatment of cancer patients].
Yasuda H
Nihon Yakurigaku Zasshi; 2019; 153(1):11-15. PubMed ID: 30643086
[TBL] [Abstract][Full Text] [Related]
9. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
10. Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period.
Boyce RW; Varela A; Chouinard L; Bussiere JL; Chellman GJ; Ominsky MS; Pyrah IT
Bone; 2014 Jul; 64():314-25. PubMed ID: 24727159
[TBL] [Abstract][Full Text] [Related]
11. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.
Kearns AE; Khosla S; Kostenuik PJ
Endocr Rev; 2008 Apr; 29(2):155-92. PubMed ID: 18057140
[TBL] [Abstract][Full Text] [Related]
12. Treatment of osteoporosis with denosumab.
Lewiecki EM
Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778
[TBL] [Abstract][Full Text] [Related]
13. RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases.
Yasuda H
World J Orthop; 2013 Oct; 4(4):207-17. PubMed ID: 24147256
[TBL] [Abstract][Full Text] [Related]
14. Discovery of the RANKL/RANK/OPG system.
Yasuda H
J Bone Miner Metab; 2021 Jan; 39(1):2-11. PubMed ID: 33389131
[TBL] [Abstract][Full Text] [Related]
15. [Anti-RANKL antibody].
Omiya T; Tanaka S
Nihon Rinsho; 2015 Oct; 73(10):1690-5. PubMed ID: 26529931
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of bone metastasis by denosumab, the human monoclonal neutralizing antibody to RANKL].
Yoneda T
Nihon Rinsho; 2012 Dec; 70(12):2165-71. PubMed ID: 23259391
[TBL] [Abstract][Full Text] [Related]
17. [Control of bone resorption by RANKL-RANK system].
Harada S; Takahashi N
Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
[TBL] [Abstract][Full Text] [Related]
18. Do RANKL inhibitors (denosumab) affect inflammation and immunity?
Ferrari-Lacraz S; Ferrari S
Osteoporos Int; 2011 Feb; 22(2):435-46. PubMed ID: 20571772
[TBL] [Abstract][Full Text] [Related]
19. Denosumab: an investigational drug for the management of postmenopausal osteoporosis.
Lewiecki EM
Biologics; 2008 Dec; 2(4):645-53. PubMed ID: 19707445
[TBL] [Abstract][Full Text] [Related]
20. RANK ligand inhibition with denosumab for the management of osteoporosis.
Lewiecki EM
Expert Opin Biol Ther; 2006 Oct; 6(10):1041-50. PubMed ID: 16989586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
